Eureka Therapeutics and City of Hope Treat First Patient with GPC3 Targeting ARTEMIS® T Cells (ECT204) for Advanced Liver Cancer

EMERYVILLE, Calif. & LOS ANGELES–(BUSINESS WIRE)–Eureka Therapeutics Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat solid tumors, and City of Hope, one of the largest cancer research and treatment organizations in the United States, today announced that City of Hope treated the first patient with GPC3-positive…